A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate [sunitinib] Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 06 Aug 2014
At a glance
- Drugs Sorafenib; Sunitinib
- Indications Liver cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Pfizer
- 23 Jun 2012 Company added in the association field as reported by EudraCT.
- 21 Apr 2012 Additional trial locations (Czech Republic, Hungary, Portugal) identified as reported by EudraCT.
- 30 Jan 2012 Actual patient number changed from 1074 to 1075 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History